Eva Van den Eynde

Summary

Publications

  1. ncbi Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 16:887-93. 2011
  2. ncbi Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Autonomous University of Barcelona, Spain
    Clin Infect Dis 48:1152-9. 2009
  3. ncbi Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:2479-86. 2012
  4. ncbi Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients
    Eva Van den Eynde
    Infectious Diseases Service, Hospital Vall d Hebron, Medicine Department, Universitat Autonoma de Barcelona, Spain
    AIDS 24:975-82. 2010
  5. ncbi Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:1453-8. 2012
  6. ncbi Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Acquir Immune Defic Syndr 59:31-8. 2012
  7. ncbi Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Antimicrob Chemother 62:793-6. 2008

Detail Information

Publications7

  1. ncbi Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 16:887-93. 2011
    ..Here, we studied the effect of abacavir, tenofovir or lamivudine addition on the suppressive activity of ribavirin in an HCV RNA replicon system...
  2. ncbi Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Autonomous University of Barcelona, Spain
    Clin Infect Dis 48:1152-9. 2009
    ..To study the feasibility of a response-guided therapy for chronic hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus (HIV) in a tertiary care hospital...
  3. ncbi Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:2479-86. 2012
    ..To assess the effectiveness of simplification to a dual antiretroviral regimen containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced HIV-1-infected patients...
  4. ncbi Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients
    Eva Van den Eynde
    Infectious Diseases Service, Hospital Vall d Hebron, Medicine Department, Universitat Autonoma de Barcelona, Spain
    AIDS 24:975-82. 2010
    ..Our main objective was to study the ability of week 12 viral response [early virologic response (EVR)] to predict long-term outcome in patients treated for 48 weeks...
  5. ncbi Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:1453-8. 2012
    ..To assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen...
  6. ncbi Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Acquir Immune Defic Syndr 59:31-8. 2012
    ..We conducted a multicenter study to analyze differences in clinical presentation of IPD between HIV-infected and non-HIV-infected adults in the prevaccine and postvaccine era...
  7. ncbi Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Antimicrob Chemother 62:793-6. 2008
    ..However, data available on the efficacy of this therapy in co-infected patients who failed a former interferon-based regimen are limited...